VALID v. Vital update

Current Food and Drug Administration (FDA) user fees for prescription drugs, generic drugs, biosimilars, and medical devices are set to expire at the end of September and draft legislation for their reauthorization is moving forward in both houses of Congress. The looming deadline for passage is important not only in terms of the user fees’ [...] Read More